Lefisyo (Levomethadone Hydrochloride)

Levomethadone works by strongly activating mu‑opioid receptors, which produces analgesia and suppresses opioid cravings. It also blocks NMDA receptors, a mechanism that may limit the development of tolerance and modulate pain pathways, resulting in effective pain control and stabilization of opioid dependence.

The appropriate dose of Lefisyo is determined by the prescribing clinician based on the individual’s medical condition, opioid tolerance, and treatment goals. Patients should follow the dosage instructions provided by their healthcare professional and not adjust the dose on their own.

Safety data for levomethadone during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers must evaluate each case individually and discuss potential risks with the patient.

To order Lefisyo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details, and any necessary import documentation.

Levomethadone is the levo‑enantiomer of methadone, offering similar opioid receptor activity with potentially reduced side‑effect burden. Both are used for opioid dependence and chronic pain, but levomethadone may provide a more predictable pharmacokinetic profile and lower risk of certain adverse cardiac effects compared with racemic methadone.

Lefisyo should be stored at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use to maintain stability.

Lefisyo is administered orally, typically as a tablet taken with water. The exact dosing schedule and whether it should be taken with food are determined by the prescribing clinician based on the patient’s therapeutic needs.

The most serious risks include respiratory depression, which can be life‑threatening, and cardiac arrhythmias such as QT interval prolongation. Other severe concerns are severe hypotension, seizures, and allergic reactions like anaphylaxis. Patients should be monitored closely, especially during initiation and dose changes.

Lefisyo should be avoided in individuals with known hypersensitivity to levomethadone or any component of the formulation, those with severe respiratory insufficiency, uncontrolled cardiac arrhythmias, or significant hepatic impairment. It is also contraindicated in patients concurrently using monoamine oxidase inhibitors.